Cidara Therapeutics, Inc.
CDTX
$19.44
$0.261.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -52.31M | -15.99M | -- | -10.33M | -3.21M |
| Total Depreciation and Amortization | 59.00K | 61.00K | -- | 56.00K | 39.00K |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | -- | 16.00K | 24.00K |
| Total Other Non-Cash Items | 1.97M | 1.05M | -- | 999.00K | 1.10M |
| Change in Net Operating Assets | 20.87M | -21.82M | -- | 2.61M | -10.67M |
| Cash from Operations | -29.41M | -36.70M | -- | -6.64M | -12.72M |
| Capital Expenditure | 0.00 | -106.00K | -- | -23.00K | -178.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -106.00K | -- | -23.00K | -178.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -76.00K | -75.00K | -- | -50.00K | -- |
| Issuance of Common Stock | 98.28M | -- | -- | -- | 8.00K |
| Repurchase of Common Stock | 0.00 | -107.00K | -- | -39.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -4.00K | -- |
| Cash from Financing | 98.21M | -182.00K | -- | -93.00K | 8.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.79M | -36.98M | -- | -6.76M | -12.89M |